Sarasota, Fla. – September 11, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.

CEO Kelvin Cooper to hold one-on-one investor meetings during three-day conference

Kelvin Cooper, Ph.D., chief executive officer of the clinical-stage biotechnology company, will deliver a virtual presentation and conduct one-on-one meetings with registered investors and potential partners. The sessions will cover Lakewood-Amedex's business and clinical development strategy, recent corporate achievements, and anticipated milestones.

Company advances Bisphosphocin class of antimicrobials targeting drug-resistant bacteria

Lakewood-Amedex is developing the Bisphosphocin® class, a novel category of fast-acting, broad-spectrum antimicrobials designed to treat infectious diseases and counter antibiotic-resistant bacterial strains including MRSA and VRE.